urokinase

Conclusion treating acute cerbral infarction with large dose of urokinase in the early stage is safe and effective if window time 、 indication and contra-indication is strictly controlled.

结论只要严格掌握溶栓治疗的时间窗、适应症及禁忌症，应用大剂量尿激酶在急性脑梗塞的超早期进行静脉溶栓治疗是安全的、有效的。

Methods: Non-glycosylated pro-urokinase was created by Asn 302-Ala 302 mutagenesis.

方法: 将302位天冬酰胺(Asn302)突变为丙氨酸(Ala302 ),构建非糖基化尿激酶原.

Subconjunctival injection urokinase combined with dexamethasone was performed 2-3 times.

药物治疗行尿激酶联合地塞米松结膜下注射,共2~次.

Study of Prevention of Tuberculosis Pleurisy Hypertrophy of Adhesion by Thoracic Drainage and an Early Intrapleural Injection of Urokinase

胸腔引流并早期注入尿激酶预防结核性胸膜炎粘连肥厚的研究

Experimental study on the prevention of postoperative pericardial adhesion with urokinase

尿激酶心包腔灌注预防术后心包粘连的实验观察

Conclusions: Intravenous urokinase thrombolysis could an effective and safe treatment for acute cerebral infarction.

结论: 尿激酶静脉溶栓治疗急性脑梗死有效且相对安全.

Objective: To identify of urokinase-type plasminogen activator ( UPA ) expression in patients with epithelial ovarian carcinoma.

目的: 探讨尿激酶型纤溶酶原激活因子 ( UPA ) 的蛋白表达与上皮性卵巢癌生物学行为的关系.

In this process, urokinase-type plasminogen activator ( uPA ) and P-selectin play a very important role.

在此过程中, 尿激酶型纤溶酶原激活物(urokinase -type plasminogenactivator,uPA ) 和P - 选择素起着十分重要的作用.

Objective To discuss the clinical effect on ventricular hemorrhage by lateral ventricular exporting and infusing Urokinase.

目的探讨侧脑室引流术及注入尿激酶治疗脑室出血的临床疗效.

PURPOSE: To study the expressions and clinical significance of urokinase-type plasminogen activator ( uPA) and uPA receptor ( uPAR) in tongue squamous cell carcinoma ( TSCC).

目的：研究尿激酶型纤溶酶原激活剂（uPA）及其特异受体（uPAR）在舌鳞癌（TSCC）中的表达及其与临床病理参数的关系。

Objective To study the relationship of TCD with apparent diffusion coefficient ( ADC) in hyperacute cerebral infarction, and to determine their roles on the outcome of intravenous thrombolytic therapy with high dose urokinase ( UK).

目的探讨脑梗死超早期经颅多普勒超声（TCD）与磁共振表观弥散系数（ADC）的关系，及二者对大剂量尿激酶静脉溶栓近期预后的意义。

Objective To explore the clinic effect of continuing drainage of cerebrospinal fluid ( CSF) by terminal cistern inserted tube, combined with pouring into urokinase treating serious subarachnoid hemorrhage ( SAH).

目的探讨腰池置管脑脊液持续外引流术联合注入尿激酶（UK）治疗重症蛛网膜下腔出血（SAH）的临床疗效。

The influence of urokinase plus in thoracic close drainage for adhesion of tuberculous pleurisy

胸腔闭式引流加尿激酶注入对结核性胸膜炎粘连的影响

Methods All 82 patients received intravenous urokinase ( UK ) for acute ischemic stroke.

方法　82例急性脑梗死患者接受尿激酶 ( UK ) 静脉溶栓治疗.

Dose and Time Effect of Clot Lysis with Urokinase in Vitro

尿激酶体外溶凝量效与时效的实验观察

Thrombolytic therapy of high dose urokinase impact for central retinal artery occlusion

大剂量尿激酶冲击溶栓治疗视网膜中央动脉阻塞

The clinical observe on effect of cerebral arterial thrombolysis with Urokinase upon acute ischemic stroke

动脉溶栓治疗急性脑梗塞临床观察

Clinical study of highly viscous semen treated by urokinase

尿激酶治疗高粘稠度精液的临床研究

Southern blot and Slot blot hybridization methods were used in this research to detect the copy numbers of pro-urokinase ( pro-UK) gene in pro-UK-expression engineering cell line ( 11G cell line).

采用DNA印迹和狭线印迹（Slot Blot）的方法，对高效表达人尿激酶原（Pro-UK）的工程细胞11G含有的pro-UK基因拷贝数进行了测定。

Conclusion: Thrombolytic therapy with broadened therapeutic window for acute cerebral infarction with low dose urokinase is beneficial and safe.

结论：小剂量尿激酶超时间窗治疗急性脑梗死安全有效。

Combination of closed thoracic drainage with urokinase and adhesive for malignant loculated pleural effusion

闭式引流联合尿激酶及黏连剂治疗恶性包裹性胸腔积液

To explore an effective treatment on severe ventricular hemorrhage, 33 patients with severe ventricular hemorrhage were perfused urokinase through installing cannulas in bilateral ventricles to drain, and liquor cerebrospinalis was replaced and drained in terminal cistern.

为探讨重度脑室出血的有效治疗方法，对33例重度脑室出血患者采用双侧脑室额角置套管尿激酶灌注冲洗引流和终池脑脊液置换引流治疗。

Comparison of thrombolytic therapy with recombinant tissue plasminogen activator and urokinase for acute myocardial infarction;

目的探讨静脉溶栓对男女急性心肌梗塞患者的疗效对比。

Thrombolytic therapy of acute MVT with Urokinase and Batroxobin is feasible, effective and safe.

尿激酶联合巴曲酶治疗MVT是有效和安全的.

D-dimer; lower extremity deep venous thrombosis; thrombolytic therapy; urokinase.

D - 二聚体; 下肢深静脉血栓形成; 溶栓治疗; 尿激酶.

Comparative quantification of the membrane-associated urokinase plasminogen activator ( uPA) on the ejaculated spermatozoa between sterile patients with asthenospermia and healthy fertile Men

弱精症男子与正常人精子膜尿激酶型纤溶酶原激活因子含量的研究

Comparison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test

重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较

Clinical study of small dose urokinase for post therapeutic window of UK thrombolysis of cerebral infarction by interventional pressor perfusion

错过溶栓时间窗的脑梗死通过动脉介入加压灌注治疗临床探讨

Effect of thrombolytic therapy by urokinase on the function of platelet

尿激酶溶栓治疗对血小板功能的影响

Comparison between intravenous thrombolytic therapy in small dose of urokinase and anticoagulation alone therapy for 2-week acute pulmonary embolism

50例急性肺栓塞2周后小剂量溶栓和单纯抗凝疗效观察